Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM - Free Report) in a research note released on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.

ALIM has been the topic of several other research reports. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price target on the stock. in a research report on Tuesday, June 25th. Alliance Global Partners reissued a neutral rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a report on Tuesday, June 25th.

Alimera Sciences Trading Up 0.2 %

Shares of NASDAQ ALIM traded up $0.01 during trading on Wednesday, reaching $5.59. The stock had a trading volume of 65,688 shares, compared to its average volume of 205,196. The company has a debt-to-equity ratio of 1.71, a quick ratio of 2.51 and a current ratio of 2.62. Alimera Sciences has a fifty-two week low of $2.61 and a fifty-two week high of $5.65. The company has a market cap of $292.85 million, a P/E ratio of -3.55 and a beta of 1.28. The business's 50-day moving average price is $5.17 and its 200-day moving average price is $4.12.

Alimera Sciences (NASDAQ:ALIM - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). The firm had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. On average, equities research analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Trading of Alimera Sciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its position in Alimera Sciences by 3.9% during the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company's stock worth $1,010,000 after acquiring an additional 6,900 shares during the last quarter. Rhumbline Advisers acquired a new stake in Alimera Sciences during the 2nd quarter valued at approximately $113,000. Fifth Lane Capital LP acquired a new position in shares of Alimera Sciences in the 1st quarter valued at about $83,000. Hillsdale Investment Management Inc. acquired a new stake in Alimera Sciences in the first quarter worth $169,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Alimera Sciences during the second quarter valued at approximately $344,000. 99.83% of the stock is owned by institutional investors.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).